Chapter 13. Case Study of Aurora-A Inhibitor MLN8054

  1. Rongshi Li and
  2. Jeffrey A. Stafford
  1. Christopher F. Claiborne1 and
  2. Mark G. Manfredi2

Published Online: 28 SEP 2009

DOI: 10.1002/9780470524961.ch13

Kinase Inhibitor Drugs

Kinase Inhibitor Drugs

How to Cite

Claiborne, C. F. and Manfredi, M. G. (2009) Case Study of Aurora-A Inhibitor MLN8054, in Kinase Inhibitor Drugs (eds R. Li and J. A. Stafford), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470524961.ch13

Editor Information

  1. Takeda San Diego, Inc., San Diego, CA 92121, USA

Author Information

  1. 1

    Department of Oncology Chemistry, Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA

  2. 2

    Department of Cancer Pharmacology, Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA

Publication History

  1. Published Online: 28 SEP 2009
  2. Published Print: 2 OCT 2009

Book Series:

  1. Wiley Series in Drug Discovery and Development

Book Series Editors:

  1. Binghe Wang

ISBN Information

Print ISBN: 9780470278291

Online ISBN: 9780470524961

SEARCH

Keywords:

  • hallmarks of cancer - unregulated proliferation under conditions;
  • Aurora-A Inhibitor MLN8054;
  • ML3 activity in HCT-116 xenograft tumor model

Summary

This chapter contains sections titled:

  • Introduction

  • MLN 8054 Case Study

  • References